Kaken Pharmaceutical Co., Ltd.
KKPCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $151 | $137 | $146 | $184 |
| - Cash | $54 | $51 | $60 | $61 |
| + Debt | $4 | $4 | $4 | $4 |
| Enterprise Value | $100 | $90 | $90 | $127 |
| Revenue | $94 | $72 | $73 | $76 |
| % Growth | 30.5% | -1.3% | -4% | – |
| Gross Profit | $59 | $39 | $40 | $42 |
| % Margin | 62.2% | 53.5% | 54.2% | 54.7% |
| EBITDA | $22 | $13 | $9 | $16 |
| % Margin | 23.4% | 17.4% | 12.9% | 21.5% |
| Net Income | $14 | $8 | $5 | $10 |
| % Margin | 14.8% | 11.1% | 7.5% | 12.6% |
| EPS Diluted | 365.42 | 212.66 | 144.79 | 251.44 |
| % Growth | 71.8% | 46.9% | -42.4% | – |
| Operating Cash Flow | $30 | $3 | $9 | $13 |
| Capital Expenditures | -$4 | -$2 | -$2 | -$3 |
| Free Cash Flow | $25 | $0 | $7 | $10 |